Study Evaluating LXR-623 in Healthy Subjects

Phase 1CompletedNCT00366522

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Healthy

Interventions

LXR-623DRUG

Eligibility

Sex: ALLMin age: 19 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: * Healthy, men or women, aged 19-50 years Exlcusion: * Use of any investigational or prescription drug within 30 days before study start * Any clinically imprtant medical disease or abnormal laboratory test results

Locations (1)

Unnamed facility

Lincoln, Nebraska, United States

Outcomes

Primary Outcomes

Safety and Tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.